Ultrabright Fluorescent Nanoconstruct Enabling Widely Accessible, High Performance Multiplexed Protein Assays
Award amount
$1,583,931Program and phase
SBIR · Phase II – Direct to Phase IIAward year
2020Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Auragent Bioscience LLC
- Proposal award date
- 2020-06-17
- Contract end date
- 2022-05-31
- UEI
- FGXDBY8YCNK1
- Solicitation number
- PA19-272
- Topic code
- NIAID
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Low-Cost Platform for Ultrasensitive Fluorescent Immunoblot
- High performance and widely accessible secretomics assay platform
- A High Sensitivity Multiplexed Immunoassay for Aging-Related Inflammation Biomarker Quantification
- Inexpensive Add-on Plasmonic Patch to Enable Ultrasensitive and High-Dynamic Range Protein Microarrays
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
5 SBIR/STTR records share this UEI (2019–2024). Reported award amounts total $5,779,375. Reported amounts are not federal obligations.
Phases: Phase II – Direct to Phase II, Phase I, Phase II
Agencies: Department of Health and Human Services